Lack of removal of nelfinavir during a haemodialysis session in an HIV-1 infected patient with hepatic and renal insufficiency [4]

Nephrology Dialysis Transplantation

Volumn 16, Issue 3, 2001, Pages 642-643

  Paci Bonaventure, S ^a   Hafi, A ^a   Quertainmont, Y ^a   Goujard, C ^a   Charpentier, B ^a   Taburet, A M ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BICARBONATE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; LAMIVUDINE; NELFINAVIR; NUCLEOSIDE ANALOG; OROSOMUCOID; PLASMA PROTEIN; PROTEINASE; PROTEINASE INHIBITOR; STAVUDINE;

ADULT; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTROLLED STUDY; DIALYSATE; DIALYSIS MEMBRANE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG PROTEIN BINDING; FEMALE; HEMODIALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; LABORATORY DIAGNOSIS; LETTER; LIVER FAILURE; LIVER TOXICITY; PATIENT SELECTION; PLASMA CLEARANCE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0035097562     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.3.642     Document Type: Letter

References (7)

1. High performance liquid chromatography method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma
2. Haemodialysis: Technical and kinetic considerations
3. Nelfinavir
4. Pharmacokinetics of nelfinavir during a haemodialysis in a patient with HIV infection
5. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease